Patent and Trademark Office (PTO) for a patent application covering a key series of adenosine kinase
inhibitors and their use in the treatment of a variety of diseases.
marketed (FDA approved) antivirals, including ribavirin (for RSV, respiratory syncytal virus) and related compounds (5 cpds); formycin analogs and polyoxometalates and dendrimers and 5 non carbocyclic adenosine analogues (totaling 11 new cpds); new apoptosis inhibitors and new cyclin-dependent kinase inhibitors (6 cpds) as well as adenosine kinase
inhibitors (3 cpds); plus miscellaneous phospolipase, attachment / penetration and bunga virus inhibitors, plus cyclohexamide and a coumadin analog (totaling 7 cpds).
In this study, Gensia scientists have shown that a certain class of ARAs, adenosine kinase
inhibitors, inhibit specific cell adhesion molecules, especially on selectin mediated adhesion, that are involved in an accumulation of neutrophils at sites of inflammation in both in-vitro and in-vivo models of inflammation.